

CURRICULUM VITAE

MAURICE McGREGOR. OQ OC

M.B., BCh., M.D., FRCP(C), FRCP(London), FACP, FACC.

EDUCATION

Postgraduate Education

- 1949-50 Senior Registrar, National Heart Hospital, London (Jan.-Dec.)
 1948-49 Registrar, Hammersmith Hospital, London (equiv. Resident) (Mar.-Dec.)
 1947-48 Intern, Hammersmith Hospital, London (Dec.-Mar.)
 Postgraduate Student, National Hospital, Queen's Square, London (Sep.-Nov.)
 Clinical Assistant, Dept. of Medicine, Witwatersrand University, Johannesburg
 (equivalent Resident) (Feb.-Aug.)
 1947 M.D. Witwatersrand. Thesis: Basilar Impression
 1946-47 Intern, Johannesburg Hospital

Medical Education

- 1936-42 University of the Witwatersrand, Johannesburg, South Africa
 1942 M.B., B.Ch., Witwatersrand (equivalent Canadian M.D.)

Undergraduate Education

- 1932-35 Michaelhouse School (South Africa)

PROFESSIONAL AND ACADEMIC APPOINTMENTS

- 2015- Physician Emeritus, McGill University Health Centre
 2013- Expert Consultant, Health Technology Assessment Unit, McGill University Health Centre
 2009-10 Steering Committee, Organ and Tissue Donation/Transplantation. Can Blood Services
 2007-09 International Expert Panel on Economic Evaluation. Institute for Quality in HealthCare,
 Germany
 2000-13 Chair, Health Technology Assessment Unit, McGill University Health Centre
 2000-03 Canadian Institutes of Health Research, Grants Committee on Health Policy and
 Systems Management
 1994-98 Chair, Steering Committee and Editor, Canadian Clinical Practice Guidelines for the
 Care and Treatment of Breast Cancer, Health Canada
 1994-06 Consultant, AÉTMIS (Agence d'évaluation des technologies et de modes d'intervention
 en santé, formerly CETS (Conseil d'évaluation des technologies de la santé du Québec)
 1988-94 Président, Conseil d'évaluation des technologies de la santé du Québec
 1987-pres Professor Emeritus, McGill University
 1984-87 Dean, Faculty of Medicine, University of Witwatersrand, Johannesburg
 1979-15 Senior Physician, Royal Victoria Hospital
 1974-79 Physician-In-Chief, Royal Victoria Hospital
 1973 Bethune Exchange Professor, Peking Med Coll, Peoples Rep. of China
 1972-75 Director, Cardiovascular Division, Royal Victoria Hospital
 1972-74 Vice-Principal, McGill University
 1967-72 Dean, Faculty of Medicine, McGill University
 1963-79 Physician, Royal Victoria Hospital
 1963-87 Professor of Medicine, McGill University
 1959-67 Co-Director, Joint Cardio-Respiratory Service of the Royal Victoria Hospital
 and the Montreal Children's Hospital
 1957-63 Associate Professor, McGill University
 Assistant Physician, Montreal Children's Hospital and Royal Victoria Hospital

- 1956-57 Physician Tutorial, Johannesburg Hospital and Witwatersrand University, (equivalent Canadian, Associate Professor)
Head, Cardiac Service, Johannesburg Hospital and Associate Director, Cardio-Pulmonary Research Unit, Council for Scientific and Industrial Research
- 1955-56 Research Fellow, Harvard School of Public Health, and Clinical Fellow, Massachusetts General Hospital, Boston, Mass.
- 1950-54 Assistant Physician Tutorial, Johannesburg Hospital, and University of Witwatersrand (equivalent Canadian, Assistant Professor)
- 1946-47 Intern, Johannesburg General Hospital.

MILITARY SERVICE

- 1942-46 Captain, South African Medical Corps. British 8th Army. US 5th Army.

HONORARY INSTITUTIONAL SERVICE

- 2005-15 Consultant. The Cole Foundation
- 2000-08 Governor, Montreal Diet Dispensary
- 1999- Governor, Portage Project
- 1994-05 Editorial Board, J. Quality in Clinical Practice
- 1990-97 Board of Governors, Royal Victoria Hospital
- 1989-90 Membre, Centre Québécois de coordination sur le SIDA
- 1979-84 Editorial Board, Circulation
- 1979-83 Board of Governors, Queen Elizabeth Hospital
- 1972-74 Conseil de la politique scientifique du Québec
- 1974-77 Vice-Pres., Montreal Neurological Hospital
- 1973-75 Member, Board of Governors, Lakeshore General Hospital
- 1972-74 President, Montreal Joint Hospitals Institute
- 1970-77 Board of Governors, Montreal Joint Hospitals Institute
- 1967-77 Board of Governors, Montreal Neurological Hospital
- 1967-77 Board of Governors, Royal Victoria Hospital
- 1967-72 Board of Governors, Montreal General Hospital

REGISTRATION

- 1963 Collège des médecins du Québec (Cardiologie)
- 1949 General Medical Council of Great Britain (Internal Medicine)
- 1942 The S.A. Medical & Dental Council (Internal Medicine)

HONOURS

- 2011 Officer of the Order of Canada
- 2011 The Dr Jill M Sanders Award of Excellence in HTA. Canadian Agency for Drugs and Technology in Health
- 2008 Cardiologue émérite 2008. l'Association des Cardiologues du Québec
- 2006 Prix « Maurice McGregor ». Agence d'évaluation des technologies et des modes d'intervention en santé
- 2001 Chevalier de l'Ordre national du Québec

2001	2001 Award, Quebec Region, Royal College of Physicians of Canada
1992	Physician-in-Chief Award, Royal Victoria Hospital
1987	Professor Emeritus – McGill University
1979	Honorary Degree. Doctor of Medicine Honoris Causa – University of Witwatersrand
1974	Ray F. Farquharson Memorial Lecturer, University of Toronto
1969	Fellow, Royal College of Physicians of London
1968	Honorary Fellowship, Royal College of Physicians of Canada

PUBLICATIONS

Refereed Papers

1. McGregor M. Electrical Alternans. Electrocardiographic Case book XVIII. Clin Proc 1946; 5:404-8.
2. McGregor M. A case of hereditary haemorrhagic telangiectasia. Clin Proc 1947; 6:94-8.
3. McGregor M. The significance of certain measurements of the skull in the diagnosis of basilar impression. Br J Radiol 1948; 21:171-81.
4. McGregor M. Angiocardiography: a new cassette changer. Br J Radiol 1949; 22:459-61.
5. Wood P, McGregor M, Magidson O, Whittaker W. The effort test in angina pectoris. Br Heart J 1950; 12:363-71.
6. McGregor M. The genesis of the electrocardiogram of right ventricular hypertrophy. Br Heart J 1950; 12:351-9.
7. McGregor M,. Angiocardiography: an aid to technique. Br J Radiol 1951; 24:28 (letter).
8. Van Lingen B, McGregor M, Meyer MJ, Jacobs HD, Braudo JL, Bothwell TH, Elliott GA Kaye J. Clinical and cardiac catheterisation findings compatible with Ebstein's anomaly of the tricuspid valve. Am Heart J 1952; 43:77-8.
9. McGregor M, Van Lingen B, Bothwell TH, Kaye J, Greenstein J, Whidbourne J, Braudo JL, Jacobs HD, Elliott GA. Fallot's tetralogy: its differentiation from pulmonic stenosis with intact ventricular septum and an inter-auricular communication (Fallot's trilogy). S A J Clin Sci 1952; 3:154-70.
10. McGregor M, Medalie M. Coarctation of the aorta. Br Heart J 1952; 14:531-3.
11. Bothwell TH, Van Lingen B, Whidborne J, Kaye J, McGregor M, Elliott GA. Patent ductus arteriosus with partial reversal of the shunt. Am Heart J 1952; 44:360-71.
12. Kaye J, Meyer B, Van Lingen B, McGregor M, Braudo JL. The radiological diagnosis of mitral valve disease. Br J Radiol 1953; 26:242-51.
13. Bradlow BA, McGregor M, Bothwell TH, Zion MM. The effect of thyroid extract in hypertension. S A Med J 1953; 27:717-21.

14. McGregor M, Bothwell TH, Zion MM, Bradlow BA. The effects of oxygen breathing on the pulmonary circulation in cases of mitral stenosis. *Am Heart J* 1953; 46:187-94.
15. McGregor M. Clinical diagnosis in congenital heart disease. *The Leech* 1953; 23:59-63.
16. Becklake MR, McGregor M, Goldman HI, Braudo JL. A study of the effects of physiotherapy on chronic hypertrophic pulmonary emphysema using lung function tests. *Dis Chest* 1954; 26:1-12.
17. Becklake MR, McGregor M, Goldman HI. The effects of pneumo-peritoneum on lung function in pulmonary emphysema. *Thorax* 1954; 9:222-5.
18. McGregor M, Zion MM, Bothwell TH. Oral hydergine in essential hypertension. *S A Med J* 1954; 28:292-4.
19. McGregor M. The diagnosis of mitral incompetence in the presence of mitral stenosis. *Acta Med Scand* 1955; 152(Suppl 3 06)11:111-24.
20. McGregor M, Baskind B. Electrical alternans in pericardial effusion. *Circulation* 1955; 11(6):837-43.
21. McGregor M, Segal N. The Rauwolfia alkaloids in the treatment of hypertension. *Br Heart J* 1955; 17(3):391-6.
22. Becklake MR, Griffith SB, McGregor M, Goldman HI, Shreve JP. Oxygen dissociation curves in sickle cell anaemia and in subjects with the sickle cell trait. *J Clin Invest* 1955; 34:751-5.
23. McGregor M, Rappaport MB, Sprague HB, Friedlich AL. The calibration of heart sound intensity. *Circulation* 1956; 13:252-6.
24. Borst HG, McGregor M, Whittenburger JL, Berglund E. The influence of pulmonary arterial and left atrial pressure on pulmonary vascular resistance. *Circ Res* 1956; 4:393-9.
25. McGregor M, Rappaport MB. Problems of ballistocardiography. *S A Med J* 1957;393-9.
26. McGregor M, Rappaport MB, Duff JH. The ballistocardiographic effects of acute vena caval ligation. *S A J Med Sci* 1957; 22:137-40.
27. Melik R, McGregor M. Reserpine and extracellular fluid volume. *N Engl J Med* 1957; 256: 1000-2.
28. Borst HG, Berglund E, McGregor M. The effects of pharmacologic agents on the pulmonary circulation in the dog. Studies on epinephrine, norepinephrine, 5-hydroxytryptamine, acetylcholine, histamine and aminophylline. *J Clin Invest* 1957; 36:669-75.
29. Borst HG, Whittenberger JL, Berglund E, McGregor M. The effects of unilateral hypoxia and hypercapnea on pulmonary blood flow distribution in the dog. *Am J Physiol* 1957; 36:1708-14.
30. Borst HG, Berglund E, Whittenberger JL, Mead J, McGregor M, Collier C. The effect of pulmonary vascular pressures on the mechanical properties of the lungs in anaesthetized dogs. *J Clin Invest* 1957; 36:1708-14.
31. Kamener R, Becklake MR, Goldman HI, McGregor M. Hyperinflation and lung function following surgery. *S A J Med Sci* 1957; 22:156.

32. Segel N, Van Lingen B, Resnekov V, McGregor M. Isolated congenital pulmonary incompetence. *S A Med J* 1957; 31:1157-9.
33. Kamener R, Becklake MR, Goldman HI, McGregor M. Respiratory function following segmental resection of the lung for bronchiectasis. *Am Rev Tuberc & Pulm Dis* 1958; 77(2):209.
34. Theron JC, Zwi S, McGregor M. A respiratory valve of low resistance. *Lancet* 1958; 1:415-6.
35. Goldberg MG, McGregor M. Persistent truncus arteriosus. *Am Heart J* 1958; 55:360-5.
36. Sandler A, McGregor M. Parenteral magnesium sulphate in coronary artery disease. *S A Med J* 1958; 32:697-9.
37. McGregor M, Davenport HT, Jagier W, Sekelj P, Gibbons JE, Demers PP. The cardiovascular effects of halothane in normal children. *Br J Anaesth* 1958; 30:398-408.
38. McGregor M. The value of an index of maximal expiratory force in the interpretation of tests of maximal ventilatory capacity. *Am Rev Tuberc* 1958; 78: 692-6.
39. Zwi S, Theron JC, McGregor M, Becklake MR. The influence of instrumental resistance on the maximum breathing capacity. *Dis Chest* 1959; 36:361-8.
40. Goetz RH, Warren JJ, Gauer OH, Patterson JL Jr, Keen EM, McGregor M. Circulation in the giraffe. *Circ Res* 1960; 8:1049-58.
41. Whittenberger JL, McGregor M, Berglund E, Borst HG. Influence of state of inflation of the lung on pulmonary vascular resistance. *J App Physiol* 1960; 15:878-82.
42. Anderson N, Sekelj P, McGregor M. The transmission of red and infra-red light through the human ear. *IRE Transactions on Biomedical Electronics. Biomed Electronics* 1961; 8:134-5.
43. Sekelj P, McGregor M. Estimation of cardiac output in man using an ear oximeter and coomassie blue dye. *IRE Transactions on Biomedical Electronics. Biomed Electronics* 1961; 8:127-33.
44. McGregor M, Becklake MR. The relationship of oxygen cost of breathing to respiratory mechanical work and respiratory force. *J Clin Invest* 1961; 40:971-80.
45. Jegier E, Sekelj P, Davenport HT, McGregor M. Cardiac output and related haemodynamic data in normal children and adults. *Can J Biochem & Physiol* 1961; 39:1747-53.
46. McGregor M, Sekelj P, Adam W. Measurement of cardiac output in man by dye dilution curves using simultaneous ear oximeter and whole blood cuvette techniques. *Circ Res* 1961; 9:1083-8.
47. McGregor M, Adam W, Sekelj P. Influence of posture on cardiac output and minute ventilation during exercise. *Circ Res* 1961; 9:1089-92.
48. McGregor M, Donevan RE, Anderson NM. Influence of carbon dioxide and hyperventilation on cardiac output in man. *J Appl Physiol* 1962; 17:933-7.
49. Kinsella D, Troup W, McGregor M. Studies with a new coronary vasodilator drug: persantine. *Am Heart J* 1962; 63:146-51.

50. Donevan RE, Anderson NM, Sekelj P, Papp O, McGregor M. Influence of voluntary hyperventilation on cardiac output. *J Appl Physiol* 1962; 17:487-91.
51. Becklake MR, Varvis CJ, Pengelly LD, Kenning S, McGregor M, Bates DV. Measurement of pulmonary blood flow during exercise using nitrous oxide. *J Appl Physiol* 1962; 17:579-86.
52. Bousvaros GA, Palmer WH, Sekelj P, McGregor M. Comparison of central and peripheral injection sites in the estimation of cardiac output by dye dilution curves. *Circ Res* 1963; 12:317-21.
53. Auld PAM, Johnson AL, Gibbons JE, McGregor M. Changes in pulmonary vascular resistance in infants and children with left-to-right intracardiac shunts. *Circulation* 1963; 27:257-60.
54. Jegier W, Sekelj P, Auld PAM, Simpson R, McGregor M. Relationship between cardiac output and body size. *Br Heart J* 1963; 25:425-30.
55. Auld PAM, Gibbons JE, McGregor M. Vasomotor tone in the pulmonary vascular bed in patients with left-to-right shunts. *Br Heart J* 1963; 25:257-61.
56. Sosa JA, McGregor M. Prenylamine in angina pectoris. *Can Med Assoc J* 1963; 89:248-51.
57. Klassen GA, Rubin JW, McGregor M. The effect of synthetic oxytocin in impaired atrioventricular conduction. *Am J Cardiol* 1963; 12:523-6.
58. Johnson AL, Klassen GA, McGregor M, Dobell ARC. Long-term electrical stimulation of the heart in Stokes-Adams disease. *Can Med Assoc J* 1963; 89:683-6.
59. Peretz DI, McGregor M, Dossetor JB. Lactic acidosis: a clinically significant aspect of shock. *Can Med Assoc J* 1964; 90:673-5.
60. Zsoter T, Farn WM, McGregor M. The effect of lipernia on peripheral blood flow. *Can Med Assoc J* 1964; 90:1203-5.
61. Davenport HT, Auld PAM, Sekelj P, Jegier W, McGregor M. Hypercarbia during light Halothane anaesthesia with neuromuscular block. *Anaesth* 1964; 25:307-11.
62. Newhouse MT, Becklake MR, Macklem PT, McGregor M. Effect of alternations in end-tidal CO₂ tensions on flow resistance. *J Appl Physiol* 1964; 19:745-9.
63. Fam WM, McGregor M. Effect of coronary vasodilator drugs on retrograde flow in areas of chronic myocardial ischemia. *Circ Res* 1964; 15:355-65.
64. McGregor M, Klassen GA. Observations on the effect of heart rate on cardiac output in patients with complete heart block at rest and during exercise. *Circ Res* 1964; 11:215.
65. Oriol A, Palmer WH, Nakhjavan FK, McGregor M. Prediction of left atrial pressure from the second sound-opening snap interval. *Am J Cardiol* 1965; 16:184-8.
66. Newhouse MT, McGregor M. Long-term Dipyridamole therapy of angina pectoris. *Am J Cardiol* 1965; 16:234-7.

67. Dawson A, Kaneko K, McGregor M. Regional lung function in patients with mitral stenosis studied with Xenon 133 during air and oxygen breathing. *J Clin Invest* 1965; 44:999-1008.
68. Goetz RH, Doyle JT, McGregor M. Cardiorespiratory dynamics in the ox and giraffe, with comparative observations on man and other animals. *Ann New York Acad Sci* 1965; 127:393-413.
69. Peretz DI, Scott FIM, Duff J, Dossetor JB, MacLean LD, McGregor M. The significance of lactic acidemia in the shock syndrome. *Annals New York Acad Sci* 1965; 119:1133-41.
70. Bousvaros GA, Campbell JE, McGregor M. Haemodynamic effects of Dipyridamole at rest and during exercise in healthy subjects. *Br Heart J* 1965; 28:331-4.
71. Scott HM, Peretz DI, Duff JH, MacLean LD, McGregor M. Effect of prolonged infusion of Isoproterenol on plasma volume, blood lactate and pyruvate in the dog. *Can J Pharmacol & Physiol* 1966; 44:29-37.
72. Smith HJ, Bousvaros GA, McGregor M. Failure of acute digitalization to influence exercise tolerance in angina pectoris. *Br Med J* 1966; 1 (May 28):1337-8.
73. Hoeschen RJ, Bousvaros GA, Klassen GA, Fam WM, McGregor M. Haemodynamic effects of angina pectoris, and of nitroglycerin in normal and anginal subjects. *Br Heart J* 1966; 28:221-30.
74. Nakhjavan FH, Palmer WH, McGregor M. Influence of respiration on venous return in pulmonary emphysema. *Circulation* 1966; 33:8-16.
75. Palmer WH, Fam WM, McGregor M. The effect of coronary vasodilation (Dipyridamole-induced) on the myocardial distribution of tritiated water. *Can J Physiol and Pharmacol* 1966; 44:777-82.
76. Dagenais GR, Oriol A, McGregor M. Haemodynamic effects of carbohydrate and protein meals in man: rest and exercise. *J Appl Physiol* 1966; 21:1157-62.
77. McGregor M, Fam WM. Regulation of coronary blood flow. *Bull New York Acad Med* 1966; 42:940-50.
78. McGregor M. Pharmacology of anti-anginal agents. *Med Coll Virginia Quarterly* 1967; 3(2):77-9.
79. Fam WM, Levene D, McGregor M. Effect of Alpha and Beta adrenergic stimulators on the total coronary vascular resistance and on resistance in the large superficial coronary vessels. *Fed Proc* 1967; 26:771.
80. Morch JE, Smith HJ, McGregor M. Quantitation of mitral regurgitation by constant infusion of Xenon 133. *Circulation* 1967; 35:501-8.
81. Smith JH, Oriol A, Morch J, McGregor M. Haemodynamic studies in cardiogenic shock: treatment with Isoproterenol and Metaraminol. *Circulation* 1967; 35:1084-91.
82. Oriol A, Sekelj P, McGregor M. Limitations of indicator dilution methods in experimental shock. *J Appl Physiol* 1967; 23:605-8.
83. Sekelj P, Oriol A, Anderson NM, Morch J, McGregor M. Measurement of indocyanine green using a cuvette oximeter. *J Appl Physiol* 1967; 23:114-20.

84. Oriol A, McGregor M. Indicator-dilution methods in estimation of cardiac output in clinical shock. *Am J Cardiol* 1967; 20:826-30.
85. Oriol A, Sekelj P, McGregor M. Limitations of indicator-dilution methods in experimental shock. *J Appl Physiol* 1967; 23:605-8.
86. Oriol A, Anthonisen N, McGregor M. Limitations of indicator dilution methods in the estimation of cardiac output in chronic lung disease. *Am Heart J* 1968; 75:589-94.
87. Fam WM, McGregor M. Effect of nitroglycerin and dipyridamole on regional coronary resistance. *Circ Res* 1968; 22:649-59.
88. Brandi G, Fam WM, McGregor M. Measurement of coronary flow in local areas of myocardium using Xenon 133. *J Appl Physiol* 1968; 24:446-50.
89. Fam WM, McGregor M. Pressure flow relationships in the coronary circulation. *Circ Res* 1969; 25:293-301.
90. Brandi G, McGregor M. Intramural pressure in the left ventricle of the dog. *Cardiol Res* 1969; 3:472-5.
91. McGregor M. Strike and the Physician. *Can Med Assoc J* 1971; 105:1139-41.
92. McGregor M. The effort test in angina pectoris. *Am J Cardiol* 1972; 30:151-2.
93. McGregor M, Becklake MR. Basic research in acupuncture analgesia. *Can Med Assoc J* 1974; 110:328-9.
94. McGregor M. The coronary collateral circulation. Editorial. *Circulation* 1975; 52:529-30.
95. McGregor M. Cardiology in a system of socialized medicine: The Canadian experience. *Am J Cardiol* 1975; 36:560-2.
96. Anturane Reinfarction Trial Group. Sulfapyrazone in the prevention of cardiac death after myocardial infarction. *N Engl J Med* 1978; 298:289-95, 333-4.
97. McGregor M, Pelletier G. Planning of specialized health facilities. *N Engl J Med* 1978; 299:179-81.
98. McGregor M. Entry into life sustaining systems: resource allocation. *Annals of the Royal College of Physicians and Surgeons of Canada*. October 1979: 276-7.
99. McGregor M. Pulsus Paradoxus. *N Engl J Med* 1979; 301:480-1.
100. Anturane Reinfarction Trial Group. Sulfapyrazone in the prevention of sudden death after myocardial infarction. *N Engl J Med* 1980; 302:250-6.
101. Anturane Reinfarction Trial Policy Committee. The Anturane reinfarction trial: Re-evaluation of outcome. *N Engl J Med* 1982; 306:1005-8.
102. McGregor M. The nitrates and myocardial ischemia. *Circulation* 1982; 66:689-92.

103. Boice JL, McGregor M. Effects of resident's use of laboratory tests on hospital costs. *J Medical Ed* 1983; 158:61-2.
104. McGregor M. The pathogenesis of angina pectoris and the role of nitrates in the relief of myocardial ischemia. *Am J Med* 1983; 74:21-7.
105. McGregor M. Myocardial ischemia: towards better use of the CCU. *Am J Med* 1984; 76:887-90.
106. Ducas J, Magder S, McGregor M. The validity of the hepatojugular reflux as a clinical test for congestive heart failure. *Am J Cardiol* 1983; 52:1299-303.
107. McGregor M, Crelinsten G. Possible interactions of indomethacin and nitrates in angina pectoris. *Am J Cardiol* 1984; 53:225-7.
108. McGregor M, Sheldon H, Dwyer D, Stefaniszyn HJ, Novick RJ, Spence PA, Salerno TA. The role of intimal hyperplasia in arterial spasm. *Can Med Assoc J* 1984; 131:329-30.
109. McGregor M. The Coronary Care Unit: a lack of consensus. *Am J Med* 1985; 78: 367-8.
110. McGregor M, Sniderman A. On pulmonary vascular resistance: a misinterpretation born of miscalculation. *Am J Cardiol* 1985; 55:217-21.
111. McGregor M. Four sins of medicine. *S A Med J* 1985; 67:643-5.
112. Langleben D, Moroz LA, McGregor M, Lisbona R. Decreased half-life of Fibrinogen in primary pulmonary hypertension. *Thrombosis Res* 1985; 40:577-80.
113. Mitchell G, McGregor M. The role of the university in the training of health professionals. *S A Med J* 1986; 70:3-4.
114. McGregor M. Mechanisms of transient myocardial ischemia. *Can J Cardiol* 1986; (Suppl A): 53A-8A.
115. Mitchell G, Mitchell D, McGregor M, Fridjohn P. Selection of medical students: are all matriculation examinations equivalent? *S A Med J* 1987; 72:416-8.
116. Eidelman D, Sami M, McGregor M, Cosio MG. The effect of the combination of theophylline and salbutamol in arrhythmias in severe COPD. *Chest* 1987; 91:808-12.
117. McGregor M. Apartheid and the academic boycott of South Africa. *N Engl J Med* 1987; 316:(16)1022-3.
118. McGregor M. Pharmaceutical "Generosity" and the Medical Profession. *Annals of the Royal College of Physicians and Surgeons of Canada*, 1988; 21:289.
119. McGregor M, Ncayiyana D. An innovative medical curriculum. *S A Med J* 1988; 74:XVII-XIX.
120. Silberberg JS, McGregor M. Restoration of flow in acute coronary obstructive syndromes: Consequences of different management strategies. *Can J Cardiol* 1989; 5:129.
121. Meyer T, Sareli P, Marcus RH, Pocock W, Berk MR, McGregor M. Mechanism underlying Kussmaul's sign in chronic constrictive pericarditis. *Am J Cardiol* 1989; 64:1069-72.

122. McGregor M. Technology and the allocation of resources. *N Engl J Med* 1989; 320:118-9.
123. Caro JJ, Trindade E, McGregor M. The risks of death and of severe nonfatal reactions with high- vs low osmolality contrast media: a meta-analysis. *AJR* 1991; 156:825-32.
124. Kimoff RJ, Cosio MG, McGregor M. Clinical features and treatment of obstructive sleep apnea. *Can Med Assoc J* 1991; 144:689-95.
125. Caro JJ, Trindade E, McGregor M. The cost-effectiveness of replacing high-osmolality with low osmolality contrast media. *AJR* 1992; 159(4):869-74.
126. McGregor M. The reuse of cardiac pacemakers. *Can J Cardiol* 1992; 8(7):697-701.
127. Roy DJ, Dickens BM, McGregor M. The choice of contrast media: medical, ethical and legal considerations. *Can Med Assoc J* 1992; 147(9):1321-4.
128. Baris E, McGregor M. The reuse of hemodialysers: an assessment of safety and potential savings. *Can Med Assoc J* 1993; 148(2):175-83.
129. Archer C, Levy AR, McGregor M. Value of routine preoperative chest x-rays: a meta-analysis. *Can J Anesth* 1993; 40(11):1022-7.
130. Jacob R, McGregor M et al. The reuse of single-use cardiac catheters: Safety, economical, ethical and legal issues. *Can J Cardiol* 1994;10 (4):413-21.
131. Levy AR, McGregor M. How has lithotripsy changed the treatment of renal stones in Quebec? *Can Med Assoc J* 1995; 153(12):1729-36.
132. McGregor M. Implementing advances in medical technology: the Canadian view. *J R Soc Med* 1995; 88(26):29-30.
133. Boivin JF, McGregor M, Archer C. Cost effectiveness of screening for primary open angle glaucoma. *J Med Screening* 1996; 3:154-63.
134. Jacob R, McGregor M. Assessing the impact of health technology assessments. *Intl J Technol Assess in Health Care* 1997; 13:68-80.
135. McGregor M. Coverage of drug costs: Reference-based pricing. *Can J Cardiol* 1998; 14(5):666-8.
136. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of over detection. *Can Med Assoc J* 1998; 159(11):1368-72.
137. McGregor M. The hepatitis C disaster. *Can Med Assoc J* 1998; 158(11):1461.
138. McGregor M, Brophy JM. Use of Abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty. *Can J Cardiol* 1999; 15(2):201-7.
139. McGregor M. Implantable Left Ventricular Assist Devices: Is it time to introduce them in Canada? *Can J Cardiol* 2000; 16(5):629-40.
140. McGregor M. The Academic Prince. *Acad Med* 2002; 77:1221-2.

141. McGregor M. Cost-utility analysis: Use QALYs only with great caution. *Can Med Assoc J* 2003; 168:433-4
142. McGregor M. Should the implantable cardiac defibrillator be used for primary prevention of sudden death? A review of issues relevant to hospital decision making. *Can J Cardiol* 2004; 20(12):1199-04.
143. McGregor M, Brophy J. End-user involvement in HTA development. A way to increase impact. *Intl J Technol Assess in Health Care*. 2005; 21:263-7.
144. Dendukuri N, Costa V, McGregor M, Brophy J,M. Probiotic therapy for the prevention and treatment of *Clostridium difficile*-associated diarrhea: a systematic review. *Can Med Assoc J* 2005; 173:167-70.
145. McGregor M. What decision makers want and what they have been getting. *Value in Health* 2006; 9(3):181-5.
146. Costa V, McGregor M, Laneuville P, Brophy JM. The Cost-Effectiveness of Stem Cell Transplantations from unrelated donors in adult patients with Leukemia. *Value in Health* 2007; 10(4):1-9.
147. McGregor M, Caro J. QALYs. Are They Helpful to Decision Makers? *Pharmacoeconomics* 2006; 24(10): 947-52.
148. Zanke B, Spencer PC, Culyer T, Longo C, McGregor M. Facing cancer costs. How will we afford hi-cost cancer therapies? *Oncology Exchange* 2007; 6(1):42-48.
149. McGregor M. Evaluation *Before* Acquisition: a hospital approach to decision-making. *Ontario Thoracic Revues* 2007; 19(2):1-4.
150. McGregor M. Paying for Technology: The Cost of Ignoring Opportunity Costs. *Healthcare Quarterly* 2010; 13(2):90-2.
151. Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, de Pouvourville G, Atella V, Kolominsky-Rabas P. IQWiG methods - a response to two critiques. *Health Econ* 2010; 19(10):1137-8.
152. Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, De Pouvourvillr G, Atella V, Kolominsky-Rabas P. The efficiency frontier approach to economic evaluation of health-care interventions. *Health Econ* 2010; 19(10): 1117-27.
153. Xie X, Dendukuri N, McGregor M. Percutaneous radiofrequency ablation for the treatment of early stage hepatocellular carcinoma: A Health Technology Assessment. *Intl J of Tech Assess in Health Care* 2010; 26(4):390-7.
154. Xie X, McGregor M, Dendukuri N. The Clinical Effectiveness of Negative Pressure Wound Therapy. A systematic review. *Journal of Wound Care* 2010; 19(11):490-5.
155. Xie X, McGregor M, KTP 532 nm laser for laryngeal lesions. A systematic review. *J Voice* 2013; 27(2):245-9.
156. Hanley JA, McGregor M, Liu Z, Strumpf EC, Dendukuri N. Measuring the Mortality Impact of Breast Cancer Screening. *Canadian J of Public Health* 2013; 104(7):e437-e442.

157. Hanley JA, Liu Z, McGregor M. The benefits and harms of breast cancer screening. *Lancet* 2013; 381(9869):800.
158. McGregor M. The GRADE recommendations. Weak recommendations are unhelpful to decision makers. *J Clin Epidemiol* 2014; 67:236-40.
159. McGregor M. Against patient involvement in clinical research. *Can Med Assoc J* 2017; 189(7):E284.

Book Chapters/Contributions to a collective peer reviewed work

1. McGregor M. Pulmonary hypertension. Tenth Hahnemann Symposium on Aging of the Lung, 1963.
2. McGregor M, Palmer WH. Mechanism of angina pectoris. In "Coronary Heart Disease". Eds: William Likoff and JH Moyer. Grune & Stratton, New York 1963; 17 8-18 1.
3. McGregor M. Mitral stenosis and pulmonary hypertension. In "The Theory and Practice of Auscultation". FA Davis Co, Philadelphia 1963; 379-383.
4. McGregor M. Pulmonary hypertension. In "Aging of the Lung". Ed: L Cander. Grime & Stratton, New York 1964; 310-321.
5. McGregor M. Hypoxia and the lung. Canadian Cardiovascular Society Conference on Oxygen Tension, 1965.
6. McGregor M. The role of oxygen tension in the regulation of pulmonary blood flow. In: "Cardiovascular and Respiratory Effects of Hypoxia". Ed: D Hatcher. S. Karger, Basel 1966; 287-306.
7. Fam WM, McGregor M. Studies on myocardial oxygen tension. In: "Cardiovascular and Respiratory Effects of Hypoxia". Ed: D Hatcher. S. Karger, Basel 1966.
8. Fam WM, Nakhjavan FK, Sekelj P, McGregor M. The effects of oxygen breathing, Nitroglycerin, and Dipyridamole in healthy and ischemic areas of the myocardium. In: Symposium on cardiovascular effects of hypoxia. Ed: D Hatcher. S. Karger, Basel 1966; 375-90.
9. McGregor M. Drugs for the treatment of angina pectoris. In: "International Encyclopedia of Pharmacology and Therapeutics". Ed: C. Raduoco-Thomas. Pergamon Press, Oxford, Section 6, 1966; 11:377-403.
10. Fam WM, McGregor M. The role of collateral circulation in evaluation of anti-anginal drugs. In: "Problems in Laboratory Evaluation of Anti-Anginal Agents". Ed: MJ Winbury. North-Holland, Amsterdam 1967; 17-25.
11. McGregor M. Pharmacology of anti-anginal agents. Med Coll Virginia Quarterly 1967; 3(2):77-9.
12. McGregor M. The effects of hypoxia on the pulmonary circulation. Entretien de Physio-Pathologie Respiratoire. Gauthier-Villars, Paris, 1967; 7e Serie:348-54.
13. McGregor M. L'Université et les services de santé au Québec. In: Autopsie d'un système. Ed: G. Blain. Les éditions Administration et Santé 1971: 59-65.
14. McGregor M. The state and the medical profession. Bull Am Coll of Surg 1971; 56(9):13-15.
15. McGregor M. Le Troisième Cinquantenaire de la Faculté de Médecine de McGill. L'Union Médicale du Canada 1971; 100:435-7.
16. McGregor M. The McGill Responsibility. Can Med Assoc J 1971; 105:1129-232.
17. McGregor M. Les perspectives d'avenir de la médecine à McGill. L'Union Médicale du Canada 1971; 101:2621-3.

18. McGregor M. Migration of medical manpower. Ed: JZ Bowers. The Josiah Macy Jr. Foundation, New York 1971, p 31-42.
19. McGregor M. Significance of myocardial flow measurement in the evaluation of the coronary patient. In: "Myocardial Blood Flow in Man". Ed: A Maseri. Minerva Med, Torino, 1972; p 287-96.
20. McGregor M, Fam WM. On the site of vasomotion in the coronary vascular bed. In: "The Study of the Systemic Coronary and Myocardial Effects of Nitrites". Ed: GG Gensini. CC Thomas, Springfield 1972; p 323-33.
21. McGregor M. Coronary Steal. A Review. Das chronisch kranke Herz. Ed: H Roskarn and H Reindel. FK Schaltauer Verlag, Stuttgart 1973; p 69-72.
22. McGregor M. Impact of health care legislation on the medical school. In: "International Aspects of the Provision of Medical Care". Ed: PW Kent. Oriel Press, England 1976.
23. McGregor M. Governments and medical schools. New Zealand Med J 1977; 85:383-5.
24. McGregor M. Les conséquences de la "Technologie Palliative" sur les services de santé. In: "Innovation Technologique et Services de Santé". Ed: FA Roberge. Université de Montréal, Montreal 1978; p 18-21.
25. McGregor M. Technology in Medicine. Asset or Liability. Report of the Proceedings of the National Symposium on Diagnostic Imaging. Health and Welfare Canada. Ottawa, October 23-26, 1978. p 17-21.
26. McGregor M. How to cut health care costs by 25% in the hospital. Means, consequences. In: "Painful Choices for Tomorrow: Health Care on Diminished Budgets". Ed: RS Tonks. The Eastern Canadian /American Health Conference, 1979.
27. McGregor M, Mustard JF, Ovier M, Sherry S. Eds: "Cardiovascular Actions of Sulfinpyrazone". Symposium Specialists Inc. Miami, USA, October 1980.
28. McGregor M. Hospital costs: Can they be cut? Millbank Memorial Fund Quarterly 1981; 59:89-98.
29. McGregor M. Les services de santé: Perspectives sur les années 80. Le point de vue d'un médecin. In: Actes du 3e colloque Jean-Yves-Rivard. Les Éditions Administration et Santé, Montréal 1982; 15-22.
30. McGregor M. L'impact de la technologie sur le système des soins. In: "Traite d'Anthropologie Médicale". Eds: J. Dufresne, F. Dumont, Y. Martin. Presses de l'Université du Québec, Québec 1985; 385-404.
31. McGregor M. Mechanism of nitrates in the relief of rest angina. In: "Motionitrates". Eds: GM Cohn & R Rittinghausen. Springer-Verlag, Berlin 1985; 193-200.
32. Elmslie K et al. Guidelines on ethical and legal considerations in anonymous unlinked HIV seroprevalence research. Can Med Assoc J 1990; 143(7):625-7.
33. McGregor M. Technology evaluation. Its value and its limitations. APMC Forum 24:1-4, 1991.

34. McGregor M. Does bioscience threaten human integrity? In: Schering Foundation Workshop Round table discussion on bioscience and society. Ed: J.J. Chermas. Springer. Berlin 1992.
35. McGregor M. Assessment of new technologies. In: Symposium on resource allocation in the intensive care unit. Annals of the Royal College of Physicians and Surgeons of Canada 1992; 25(1):55-6.
36. McGregor M. L'évaluation des technologies au Québec: Le conflit des coûts par rapport à l'efficacité et la sécurité. XHI' colloque Jean-Yves-Rivard: La gestion et l'évaluation des technologies de la santé, 1992. Montreal, Quebec. 1993; 27-31.
37. McGregor M. Cholesterol and Coronary Disease: Intervention Strategies. Conseil d'évaluation des technologies de la santé du Québec. Montréal: CETS, 1993. ISBN 2-550-27185-8.
38. McGregor M. Can our health services be saved by technology evaluation. The Québec experience. Clin Invest Med 1994; 17(4):334-42.
39. McGregor M. Technology evaluation in Sub-Saharan Africa. Can the Canadian experience be of use? S A Med J 1994; 84(9):585-86.
40. McGregor M. Implementing advances in medical technology: the Canadian view. J R Soc Med 1995; 88(526):29-30.
41. Boivin J-F, McGregor M. Le Dépistage du glaucome primitif à angle ouvert. Conseil d'évaluation des technologies de la santé du Québec. Montréal: CETS, 1995. ISBN 550-29221-9.
42. Archer C, McGregor M. Use of contrast media in Québec : a Follow-up. Conseil d'évaluation des technologies de la santé du Québec. Montréal-CETS, 1995.
43. Hanley JA, McGregor M. Le dépistage du cancer de la prostate. Conseil d'évaluation des technologies de la santé du Québec. Montréal-CETS, 1995. ISBN 2-550-2674-8.
44. McGregor M, Jacob R. Critères et processus de décision pour la couverture des médicaments coûteux au Québec. Rapport préparé pour la Sous-Ministre de la Santé et des Services Sociaux. 28 Aout 1998.
45. Steering Committee, Canadian Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. M. McGregor, Editor and Chair, Steering Committee. Can Med Assoc J 1998; 158(3 Suppl):S1-83.
46. McGregor M. The Ethics of Waiting. In: Do We Care? Renewing Canada's Commitment to Health. Ed: Somerville M. McGill-Queen's University Press. Montreal, 1999, pp 121-4.
47. McGregor M. Implantable Left Ventricular Assist Devices: Should they be used in Québec? Conseil d'évaluation des technologies de Québec. Montréal, CETS. 2000. ISBN 2-550-35678-0
48. McGregor M. Evaluation of a safety device to prevent needlestick injuries. The Technology Assessment Unit (TAU), McGill University Health Centre. Montréal. 2002. Available from: <https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Needlestick.pdf>
49. McGregor M. Should the MUHC Initiate an Antiviral Treatment Programme for Patients with Chronic Hepatitis C? The McGill University Health Centre. 2002, Oct. 8. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/MUHC_HC.pdf

50. Bourgault C, McGregor M. Should the MUHC use Mitoxantrone in the Treatment of Multiple Sclerosis? The McGill University Health Centre. 2002, Dec. 2. Available from: <https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Mitoxantrone.pdf>
51. Chen J, Penrod J, McGregor M. Should the MUHC use low-molecular-weight heparin in inpatient treatment of deep vein thrombosis with or without pulmonary embolism? The McGill University Health Centre, February 6, 2003 . Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Heparin_report_Feb.6.pdf
52. McGregor M. Should the MUHC approve the use of colorectal stents? The McGill University Health Centre, March 13, 2003. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Stents_colorectal_Feb_2003.pdf
53. McGregor M. Eprex and pure red cell aplasia. What should be MUHC policy for hemodialysis patients? The McGill University Health Centre, April 25, 2003. Available from: <https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Eprex.pdf>
54. McGregor M, Chen J. Use of the Implantable Cardiac Defibrillator (ICD) at the McGill University Health Centre (MUHC), September 10, 2003. Available from: <https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/icd.pdf>
55. Chen J, McGregor M. The Gastric Banding Procedure. An Evaluation. Technology Assessment Unit of the McGill University Health Centre. April 27, 2004. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Gastric_Banding_FINAL_Apr27.pdf
56. Dendukuri N, McGregor M, Brophy J. The use of Probiotics in the Prevention and Treatment of C. Difficile Diarrhea. Technology Assessment Unit. McGill University Health Centre. December 10, 2004. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/PROBIOTICS_Report_5Final.pdf
57. Costa V, Brophy J, McGregor M. Transplantation of Allogeneic Hematopoietic Stem Cells from Unrelated Donors in Adult Patients at the MUHC. Technology Assessment Unit. McGill University Health Centre. April 20, 2005. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Stem_Cells_report_20April2005_FinalVersion.pdf
58. Costa V, Brophy J, McGregor M. Vacuum-Assisted Wound Closure Therapy (V.A.C. ®) Technology Assessment Unit. McGill University Health Centre. July 11, 2005. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/VAC_REPORT_FINAL.pdf
59. Erickson L, Costa V, McGregor M. Use of Intraoperative Neurophysiological Monitoring during Spinal Surgery. Technology Assessment Unit. McGill University Health Centre. July 7, 2005 Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/SPINAL_MONITORING_Final.pdf
60. Costa V, McGregor M, Brophy J. The use of mitoxantrone in the treatment of patients with multiple sclerosis. Report Update. Technology Assessment Unit. McGill University Health Centre. March 16, 2006. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/mitoxantrone_report_May23FINAL.pdf

61. McGregor M, Costa V. Should the McGill University Health Centre use safety devices to reduce needlestick injuries associated with intravascular infusions? Report Update. Technology Assessment Unit. McGill University Health Centre. May 23, 2006. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/needlestick_update_May2006_FINAL.pdf
62. Erickson L, McGregor M. Wait times at the MUHC 1. Diagnostic imaging, joint replacement, Cancer care, sight restoration, cardiac care. Technology Assessment Unit. McGill University Health Centre. September 19, 2006. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait_Times_Report_No_1_final.pdf
63. Erickson L, McGregor M. Wait times at the MUHC 2. Selected Divisions of the MUHC Departments of Medicine and Surgery. Technology Assessment Unit. McGill University Health Centre. September 8, 2006. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait_Times_Report_No_2_final.pdf
64. McGregor M, Atwood CV. Wait times at the MUHC. No. 3 Fracture management. Technology Assessment Unit. McGill University Health Centre. May 4, 2007 Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait_Time_Fractures_May2007_Final.pdf
65. Costa V, McGregor M, Brophy J. Pulsatile machine perfusion compared to cold storage in kidney preservation. Joint Technology Assessment Unit (MUHC/CHUM). May 10, 2007 Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/machine_perfusion_May_10.pdf
66. McGregor M, Atwood CV. Wait times at the MUHC. No 4. Diagnostic Imaging Revisited. Adult Hospitals of the MUHC. Technology Assessment Unit. McGill University Health Centre. May 4, 2007. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Wait_times_radiology.pdf
67. McGregor M. The impact of TAU reports. Technology Assessment Unit. McGill University Health Centre. February 1, 2008. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/FINAL_TAU_IMPACT_REPORT_FEB_2_008.pdf
68. Atella V, Caro J, de Pouvourville G, Henry D, McGregor M, McGuire A, Nord E, Siebert U. Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System. Report prepared for IQWiG [Institute for quality and efficiency in health care] Dillener Straße 27. D-51105 Cologne. Jan 24 2008.
69. Xie X, Dendukuri N, McGregor M. Comparison of Coblation Tonsillectomy and Electrocautery Tonsillectomy in Paediatric Patients. Technology Assessment Unit. McGill University Health Centre. November 12, 2008 Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Coblation_ND_MMG_LFM_Final.pdf
70. Caro J. (Chair), Atella V, de Pouvourville G, Henry D, McGregor M, McGuire A, Nord E, Siebert U. (Members of the IQWiG International Expert Panel) Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System) IQWiG. Institute for Quality and Efficiency in Health Care. 2009. Dillener Straße 27D-51105 Cologne. Germany.
71. Nassef M, Dendukuri N, McGregor M. L'utilisation des implants Carmustine (Gliadel Wafers) chez les patients atteints de gliome malin. Unité de l'évaluation des technologies du CUSM. Avril 2009. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/GLIADEL_June_4_09.pdf

72. Esfandiari S, Dendukuri N, McGregor M. Clinical efficacy and cost of Allogenic Acellular Dermal Matrix (AA DM) in implant-based breast reconstruction of post mastectomy cancer patients. Technology Assessment Unit of the McGill University Health Centre. April 20, 2009. Available from:
https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/DERMAMATRIX_FINAL_JUNE_09.pdf
73. McGregor M. Opportunity Costs Associated with Technology Expansion in the Hospital. Technology Assessment Unit of the McGill University Health Centre. May 5, 2009. Available from:
https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Budget_Creep_TAU_JULY_12_2009_FINAL.pdf
74. Lapointe A, McGregor M. La microchirurgie endoscopique transanale (TEM). DETMIS CHUM. juillet 2009.
<http://www.chumtl.gc.ca/userfiles/File/PUBLICATIONS/DETMIS/La%20microchirurgie%20endoscopique%20transanale.pdf>
75. Pan I, Dendukuri N, McGregor M. Efficacy and cost-effectiveness of Collatamp-G for infection prophylaxis in cardiac surgery. Technology Assessment Unit of the McGill University Health Centre. November 30, 2009. Available from:
https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/COLLATAMP_CARDIAC_REPORT.pdf
76. Xie X, McGregor M, Dendukuri N. Radio-frequency ablation for the treatment of Barrett's oesophagus: A systematic review and cost analysis. Technology Assessment Unit of the McGill University Health Centre. November 12, 2009. Available from:
https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/BARRETTs_ESOPHAGUS_REPORT.pdf
77. McGregor M, Esfandiari S. Transcatheter Aortic Valve Implantation (TAVI) at the MUHC: a Health Technology Assessment. Technology Assessment Unit of the McGill University Health Centre. December 15, 2009. Available from:
https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/TAVI_REPORT.pdf
78. Xie X, McGregor M, Dendukuri N. The use of probiotics in the prevention and treatment of *Clostridium Difficile* diarrhoea: An update. Technology Assessment Unit of the McGill University Health Centre. November 25, 2009. Available from:
https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/PROBIOTICS_REPORT.pdf
79. Nassef M, McGregor M. The use of Matrix Coils in the Treatment of Cerebro-vascular Aneurysms: An Update. Technology Assessment Unit of the McGill University Health Centre. July 9, 2009. Available from:
https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/MATRIX_COILS_REPORT.pdf
80. Xie X, Dendukuri N, McGregor M. Percutaneous Radio-frequency Ablation for treatment of hepatocellular carcinoma. Technology Assessment Unit of the McGill University Health Centre. July 30, 2009. Available from:
https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/RFA_and_Liver_Cancer_FINAL.pdf
81. Pan I, McGregor M. Efficacy, safety and cost of ultrafiltration for the management of acute decompensated heart failure. Technology Assessment Unit of the MUHC. May 31, 2010. Available from:
https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Ultrafiltration_FINAL.pdf

82. Xie X, McGregor M. Negative Pressure Wound Therapy (NPWT). (Update of report 19). Technology Assessment Unit of the MUHC. June 25, 2010. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/NPWT_FINAL.pdf
83. Pan I, Dendukuri N, McGregor M. Argon beam coagulation in orthopaedic, and thoracic surgery at the MUHC: a brief report. Technology Assessment Unit of the MUHC. November 26, 2010. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Argon_Beam_Coagulation_FINAL.pdf
84. Sinclair A, McGregor M, Xie X. Aortic valve bypass (apicoaortic conduit) in adult degenerative aortic stenosis. Technology Assessment Unit, MUHC. February 2011. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/AorticValveBypass_FINAL.pdf
85. Dendukuri N, Xie X, McGregor M. Fiducial markers for improving treatment margins in radiotherapy for prostate cancer. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); Mini HTA: 2011 Jun 16. Report no. 52. 7 p. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/Muhc_tau_MiniHTA_2011_52_FdMk.pdf
86. McGregor M, Sinclair A. Drug eluting stents: What should be the indications for their use at the MUHC? Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2011 Dec 20. Report no. 55. 29 p. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2011_55_destents.pdf
87. Xie X, Nicolau I, McGregor M, Dendukuri N. Subglottic secretion drainage endotracheal tubes for prevention of ventilator-associated pneumonia. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2011 Dec 21. Report no. 56. 38 p. Available from: https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2011_56_SSD.pdf
88. Xie X, McGregor M. 532 nm KTP Laser for Vocal Fold Surgery. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 April 24. Report no. 61 16 p. Available from: http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_61_ktp_a.pdf
89. Xie X, McGregor M. Video Capsule Endoscopy for Obscure GI Bleeding and Crohn's Disease (Update of Report 7). Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 June 13. Report no. 60. 24 p. Available from: http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_60_vce.pdf
90. Sinclair A, Dendukuri N, McGregor M. Use of serum calcitonin levels in treatment decisions for adult patients in the intensive care unit. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012, June 13. Report no. 62. 20 p. Available from: http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_62_procalcitonin.pdf
91. Nicolau I, Pan I, Xie X, McGregor M, Dendukuri N. Drotrecogin Alfa (Activated) in Severe Sepsis: a systematic review of observational studies. (Update of report 29). Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 , July 25. Report no. 58 12 p. Available from: http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_58_sepsis_a.pdf
92. McGregor M, Xie X. Hyaluronic Acid Fat Graft Myringoplasty or Epidisk Tympanoplasty (ET). Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 , Aug 29. Report no. 69. 5 p. Available from: http://www.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2012_69_epidisk.pdf

93. McGregor M. The Impact of Reports of the Technology Assessment Unit of McGill University Health Centre. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012, Sept 13. Report no. 65. 5 p. Available from:
http://www.mcgill.ca/tau/sites/mcgill.ca/tau/files/muhc_tau_2012_65_impact.pdf
94. McGregor M. The Hybrid Operating Room. Should one be available for Cardiovascular-Thoracic procedures in the MUHC? Montreal (Canada): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 Nov 6. Report no. 67. 12 p.
https://secureweb.mcgill.ca/tau/sites/mcgill.ca/tau/files/muhc_tau_2012_67_hybrid.pdf
95. Xie X, Dendukuri N, McGregor M. Single-dose Intraoperative Radiotherapy Using Intrabeam® for Early-stage Breast cancer: A Health Technology Assessment. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012, Report no. 63, 26p.
https://secureweb.mcgill.ca/tau/sites/mcgill.ca/tau/files/muhc_tau_2012_63_intrabeam.pdf
96. Nicolau I, Xie X, McGregor M, Dendukuri N. Evaluation of Acellular Dermal Matrix for Breast Reconstruction: An Update. Montreal (Canada): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012 Nov 15. Report no. 59. 39 p.
https://secureweb.mcgill.ca/tau/sites/mcgill.ca/tau/files/muhc_tau_2012_59_dermalmatrix.pdf
97. Sinclair A, Xie X, McGregor M. Transcatheter aortic valve implantation (TAVI) in patients with aortic stenosis. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2013 Aug 31. Report no. 70. 30p.
https://secureweb.mcgill.ca/tau/sites/mcgill.ca/tau/files/muhc_tau_2013_70_tavi.pdf
98. Sinclair A, Xie X, McGregor M. Surgical aortic valve replacement with the ATS Enable sutureless aortic valve for aortic stenosis. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC). 2013. Sept 2. Report No 71. 14p.
https://secureweb.mcgill.ca/tau/sites/mcgill.ca/tau/files/muhc_tau_2013_71_suavr_a.pdf
99. Xie X, Dendukuri N, McGregor M. Single-dose Intraoperative Radiotherapy Using Intrabeam® for Early-stage Breast cancer: A Health Technology Assessment. Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012, Rep no. 63, 26p.
https://secureweb.mcgill.ca/tau/sites/mcgill.ca/tau/files/muhc_tau_2012_63_intrabeam.pdf
100. Sinclair A, Nicolau I, Xie X, Dendukuri N, McGregor M. The effectiveness and safety of rituximab (anti- CD20) in neurologic autoimmune diseases. Montreal (Canada): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2013 August 30 Report no. 64. 79 p. Available from:
https://secureweb.mcgill.ca/tau/sites/mcgill.ca/tau/files/muhc_tau_2013_64_rituximab.pdf

Selected Abstracts

1. Warren JJ, Patterson JL, Doyle JT, Gauer OH, Keene EN, McGregor M, Goetz RH. Circulation and respiration in the giraffe. Proc Thirtieth Scientific Session of American Heart Association. 1957.
2. McGregor M, Becklake MR. The oxygen cost of breathing. Fed Proc 1959; 18:102.
3. McGregor M, Becklake MR. The oxygen cost of breathing. Estimates based on respiratory muscle force. Fed Proc 1960; 19:374.
4. McGregor M, Adam W, Sekelj P, Peel R, Peters J, Pierer A, Potteray R. The influence of posture on cardiac output during exercise. The Physiologist 1960; (Aug):3.
5. Gibbons JE, McGregor M, Johnson AL. Ventricular septal defect in infancy. Natural history, medical mortality, hemodynamic studies, selection and timing for surgery. Thirteenth Annual Meeting Canadian Heart Association. 1960.
6. McGregor M, Sakelj P, Adam WS. Cardiac output using a modified ear oximeter and coomassie blue dye. Validation of calibration technique. Thirteenth Annual Meeting Canadian Heart Association. 1960.
7. Sakelj P, McGregor M, Adam WS, Jegier W, Beaudry P, Terri A. A simplified method for the measurement of cardiac output using dye dilution principles and coomassie blue dyes. Proc Can Soc Clin Invest. January 1960.
8. Johnson AL, Dobell ARC, Klassen GA, Palmer WH, McGregor M. Therapy in Stokes-Adams disease by electrical stimulation. Fourteenth Annual Meeting Canadian Heart Association. November 1961.
9. Auld PAM, Davenport HT, Sekelj P, Jegier W, Beaudry P, McGregor M. The effect of increased PCO₂ on cardiac output during respiratory control in the anaesthetized child. Can Med Assoc J 1962; 86:212.
10. Kinsella D, Troup W, Palmer WH, McGregor M. The therapeutic effects of "coronary dilator" drugs. Can Med Assoc J 1962; 86:222.
11. Sekelj P, Anderson J, McGregor M. Whole blood cuvette oximeter for estimation of dye concentration. Fed Proc 1962; 21:135.
12. Bousvaros G, Palmer WH, Sekelj P, McGregor M. A comparison of central and peripheral injection sites in the estimation of cardiac output by indicator dilution methods. Can Med Assoc J 1962; 86:212.
13. McGregor M. The relief of angina pectoris. Mechanisms of action of coronary "vasodilators". Forty Third Annual Session American College of Physicians. April 1962.
14. McGregor M. The mechanisms of angina pectoris. Seventh Hahnemann Symposium on Coronary Heart Disease. Philadelphia 1962.
15. McGregor M, Donevan RE, Anderson NM. Influence of carbon dioxide and hyperventilation on cardiac output in man. Fed Proc 1962;21:135.

16. Bousvaros GA, Fam WM, McGregor M. The effects of nitroglycerin on the hemodynamic response to upright exercise in normal and anginal subjects. Proceedings of the Canadian Federation of Biological Sciences, 1962.
17. Newhouse M, Becklake MR, McGregor M. Respiratory work during voluntary (hypocapneic) ventilation and during CO₂-driven (hypercapneic) ventilation. Proceedings of the Canadian Federation of Biological Societies 1962.
18. McGregor M, Donevan RE, Auld PAM, Sekelj P. Influence of PCO₂ and minute ventilation on cardiac output. International Congress of Physiological Sciences, 1962.
19. Bousvaros GA, Sekelj P, McGregor M. Cardiac output estimation by dye dilution technique using an automatic calibrated ear oximeter and a peripheral injection site. Fourth World Congress of Cardiology, 1962.
20. Palmer WH, Zsoter T, McGarry EE, McGregor M. The effects of nitroglycerine on cardiac metabolism in dogs. Annual Meeting Canadian Cardiovascular Society, 1962.
21. Auld PAM, Jegier W, Moralis F, Gibbons JE, McGregor M. Increased pulmonary vascular tone in acyanotic congenital heart disease with normal vascular resistance. Annual Meeting Canadian Cardiovascular Society, 1962.
22. Zsoter T, Fam WM, McGregor M. Effect of lipemia on peripheral blood flow. Canadian Cardiovascular Society, 1963.
23. Peretz DI, McGregor M, Dossetor JE. Lacticacidosis: a clinically significant aspect of shock. Canadian Cardiovascular Society, 1963.
24. Newhouse M, Becklake MR, Macklem PT, McGregor M. Mechanical work of respiration during voluntary (hypocapneic) hyper-ventilation and CO₂-driven hyper-ventilation. Fed Proc 1963; 22:281.
25. Palmer WH, Zsoter T, Terri A, Fam WM, McGregor M. Measurement of coronary blood flow using 4 amino antipyrine. CMAJ 1963;88:265.
26. Johnson AL, Klassen GA, McGregor M. Long-term electrical stimulation of the heart for Stokes-Adams disease. Thirty-second Annual Meeting Royal College of Physicians and Surgeons of Canada, 1963.
27. McGregor M, Palmer WH. Pharmacological relief of angina pectoris. Thirty-second Annual Meeting of the Royal College of Physicians and Surgeons of Canada, 1963.
28. McGregor M. Diagnosis of mitral stenosis with moderate and severe pulmonary hypertension. Ninth Hahnemann Symposium on Theory and Practice of Auscultation. Philadelphia, 1963.
29. Palmer WH, Zsoter T, Fam WM, McGregor M. Measurement of coronary blood flow using 4-amino antipyrine (P). Circulation 1963;28:782.
30. Hoeschen RJ, Bousvaros GA, Klassen GA, McGregor M. Hemodynamic effects of nitroglycerine in Man. Canadian Society for Clinical Investigation, 1964.

31. McGregor M, Klassen GA. The effects of heart rate on cardiac output in patients with complete heart block at rest and during exercise. Symposium on Structure and Function of the Heart, 1964.
32. Fam WM, McGregor M. Effects of coronary vasodilator drugs on retrograde flow in areas of chronic myocardial ischemia. *Fed Proc* 1964; 23:565.
33. Bousvaros GA, Doman G, McGregor M. Comparison of effects of nitroglycerine and Dipyridamole (persantin) on the hemodynamics of upright exercise in man. Seventh Inter American Congress of Cardiology, 1964.
34. McGregor M, Klassen GA, Johnson AL. The effects of heart rate on cardiac output in patients with complete heart-block at rest and during exercise. Seventh Inter-American Congress of Cardiology, 1964.
35. Oriol A, Palmer WH, Nakhjavan F, McGregor M. Prediction of left atrial pressure from the second sound opening snap interval. Seventh Inter American Congress of Cardiology, 1964.
36. Scott HM, Peretz DI, Duff JH, McGregor M, MacLean LD. Studies on isoproterenol as a potential adjuvant shock therapy. Seventh Inter-American Congress of Cardiology, 1964.
37. McGregor M, Bousvaros GA, Hoeschen RJ, Klassen GA, Fam W. The mechanism of action of nitroglycerine. Fourth European Congress of Cardiology, 1964.
38. Dawson A, Kaneko K, McGregor M. Effect of oxygen on the distribution of inspired gas and blood flow in the lungs in mitral stenosis. *Circulation* 1964; 30:111-64.
39. Fam WM, McGregor M. Contrasting action of nitroglycerine and diapyridamole on the peripheral coronary pressure in dogs with chronic myocardial ischemia. *Circulation* 1964; 30:111-64.
40. Nakhjavan FK, Palmer WH, McGregor M. Abnormal patterns of venous return in chronic cor pulmonale. *Circulation* 1964; 30:3-132.
41. Palmer WH, Fam WM, Zsoter T, McGregor M. Effect of diapyridamole on myocardial tissue perfusion. *Circulation* 1964;30:3-137.
42. McGregor M, Fam WM, Bousvaros G, Hoeschen R. Relief of angina pectoris by nitroglycerine. Royal College and Physicians and Surgeons of Canada, 1965.
43. Dawson A, Kaneko K, McGregor M. Distribution of inspired gas on pulmonary blood flow in mitral stenosis. Fourteenth Meeting of American College of Cardiology, 1965.
44. Fam WM, Sekelj P, McGregor M. Contrasting effects of nitroglycerine and diapyridamole on myocardial oxygen tension in dogs with areas of chronic myocardial ischemia. Fourteenth Meeting of the American College of Cardiology, 1965.
45. Palmer WH, Fam WM, McGregor M. Effect of diapyridamole on myocardial tissue perfusion. *Fed Proc* 1965; 24:529.
46. Dagenais GR, Oriol A, McGregor M. Effets d'un apport riche en proteines sur le débit cardiaque au repos et pendant l'exercice. Canadian Federation of Biological Sciences, 1965.

47. Palmer WH, Fam WM, Zsoter T, McGregor M. Effect of diapyridamole on myocardial tissue perfusion. *Circulation* 1965; 30:137.
48. Brandi G, Fam WM, McGregor M. Estimation of coronary flow using intramyocardial injections of radio-active tracers. *Circulation* 1965; 33:(Suppl 3):64.
49. Morch JD, Smith HJ, McGregor M. Quantitation of mitral regurgitation with xenon 133. *American Society for Clinical Investigation*, 1966.
50. Dagenais JR, McGregor M. Hemodynamic effects of carbohydrate and protein rich meals in normal men at rest and during exercise. *Fed Proc* 1966; 25:267.
51. Fam WM, Nelligan D, McGregor M. A Nitroglycerine and diapyridamole: two vasodilators with Different sites of action in the coronary vascular tree. *Circulation* 1966;(Suppl 3).
52. Brandi G, Fam WM, McGregor M. An estimation of coronary flow using intramyocardial injections of Radio-active tracers. *Circulation* 1966;34:3-64.
53. Fam WM, Levene D, McGregor M. Effect of alpha and beta adrenergic stimulation on the total coronary vascular resistance and on resistance in the large superficial coronary vessels. *Fed Proc* 1967; 26:771.
54. Oriol A, Sekelj P, McGregor M. Limitations of indicator dilution methods in experimental shock. *Federation of Biological Societies*, 1967.
55. Brandi G, McGregor M. Intramural pressure in the left ventricle of the dog. *Circulation* 1967; 36:11-75.
56. McGregor M, Oriol A, Anthonisen NR. Limitation of dye-dilution methods in estimation of cardiac output in chronic respiratory disease. *Circulation* 1967; 36:11-177.
57. Fam WM, Yudin HS, McGregor M. Large and small coronary vessel resistance. *Fed Proc* 1968; 27(2):63.
58. Cairns JA, McGregor M, Klassen GA. Infarct size from serial CPK; Relation to time of evolution and incidence of power failure. *Annual Meeting of the American Heart Association*. November 18, 1974.
59. McGregor M, L'Abbate A, Mildenberger RR, Klassen GA. The role of autoregulation in transmural distribution of coronary flow in the canine left ventricular wall. *Br Heart J* 1976; 38:880.
60. Meyer T, Sareli P, Marcus R, Berk M, Dinicola G, McGregor M. Mechanism and underlying Kussmaul's sign in constrictive pericarditis. *Circulation* 1985; 72-11:449.
61. Baris E, Coûtet S, McGregor M. The reutilisation of hemodialysers. *Seventh Annual Meeting (ISTAHC) International Society of Technology Assessment in Health Care*. Helsinki. June 1991.
62. Caro JJ, Tessier G, Trindade E, McGregor M. Screening for breast cancer: estimates of health effects and of costs. *Seventh Annual Meeting (ISTAHC) International Society of Technology Assessment in Heath Care*. Helsinki. June 1991.

63. Caro JJ, Trindade E, McGregor M. Costs of reduction of risk by use of low osmolar contrast media. Seventh Annual Meeting (ISTAHC) International Society of Technology Assessment in Health Care. Helsinki. June 1991.
64. McGregor M. Cost/safety decisions in angiography: LOM or HOM? Reuse of catheters? The Society for Cardiac Angiography, Charleston, South Carolina, U.S.A. May 1992.
65. Archer C, Levy A, Lortie F, McGregor M. Efficacy of routine preoperative chest X-ray in Quebec. Eighth Annual Meeting (ISTAHC) International Society of Technology Assessment in Health Care. Vancouver. June 1992.
66. Coûet S, Archer C, Caro JJ, McGregor M, Trindade E. Solid organ transplantation in Quebec. Eighth Annual Meeting , International Society of Technology Assessment in Health Care. Vancouver. June 1992.
67. Caro JJ, Trindade E, McGregor M. The cost-effectiveness of cardiac transplantation. Eighth Annual Meeting (ISTAHC) International Society of Technology Assessment in Health Care. Vancouver. June 1992.
68. Caro JJ, Trindade E, McGregor M. Survival, costs and cost-effectiveness of cardiac transplantation. Satellite Symposium 3 - Cardiothoracic Surgery. Cardiovasc J South Afr 1992; 3(4 Suppl):16.
69. McGregor M. Communicating the findings of research to health care decisions makers. International Society of Technology Assessment in Health Care (9th. Annual Meeting) ISTAHC, Sorrento (Naples) Italy. May 1993.
70. Levy AR, Blais R, Hanley JA, Coûet S, McGregor M. Geographic variations in surgical rates in the province of Quebec: predictors and economic consequences. International Society of Technology Assessment in Health Care (9th. Annual Meeting) ISTAHC, Sorrento (Naples) Italy, May 1993.
71. McGregor M. Clinical Practice Guidelines for the Treatment of Breast Cancer. The National Forum on Breast Cancer. Montréal. 1993.
72. Jacob R, Archer C, McGregor M. Should cardiac catheters designed for single use be reused?" International Society of Technology Assessment in Health Care (10th. Annual Meeting) ISTAHC, Baltimore, Maryland, U.S.A. June 1994.
73. Levy AR, McGregor M. The impact of renal lithotripsy on the use of resources in the Quebec health care system. International Society of Technology Assessment in Health Care (10th. Annual Meeting) ISTAHC, Baltimore, Maryland, U.S.A. 1994;(June 19-22).
74. Boivin JF, McGregor M. Screening for open-angle glaucoma. ISTAHC Eleventh Annual Meeting, Stockholm, June 6-7, 1995.
75. McGregor M, Hanley JA. Prostate cancer screening: The problem of over-detection. ISTAHC Eleventh Annual Meeting. Stockholm, June 4-7, 1995.
76. Hanley JA, McGregor M. Prostate cancer screening: Efficacy of surgery? International Society of Technology Assessment in Health Care (11th. Annual Meeting) ISTAHC, Stockholm, Sweden, 1995; (June 4-7).

77. McGregor M, Boivin JF. Screening for primary open-angle glaucoma. Scientific basis of health services. London, England. Oct. 2, 1995.
78. McGregor M, Levy A. Variations in rates of tonsillectomy, adenoidectomy and myringotomy in Quebec. Twelfth Annual Meeting of the International Society of Technology Assessment in Health Care. San Francisco. June 25, 1996.
79. McGregor M. Screening for cancer of the prostate. Health policy perspective ISTAHC. Seminar on Health Systems, Innovation and Technology Assessment. L'Esterel, Quebec Jan. 31, 1997.
80. McGregor M. Debate on PSA Screening. The case against. National Prostate Cancer Forum. Toronto March 1, 1997.
81. Caro JJ, Klittich W, McGregor M. What role should cost-effectiveness ratios play in the decision making process? 14th Annual Meet, Int Soc of Tech Assess in Health Care. Ottawa, June 1998.
82. McGregor M. Clinical practice guidelines for the treatment of breast cancer. Annual meeting of The International Society of Technology Assessment in Health Care. Edinburgh, Scotland. June 21, 1999.
83. McGregor M. Assessing the policy impact of technology assessments. Annual meeting of the International Society of Technology Assessment in Health Care. Edinburgh, Scotland. June 21, 1999.
84. McGregor M. Cardiovascular care should not be privatized. Canadian Cardiovascular Society. Quebec, Quebec, October 22, 1999.
85. McGregor M. Cost-utility analysis. The quality of QALYs. Seventh annual international meeting of The International Society for Pharmacoeconomics and Outcomes Research. Arlington, USA May 22, 2002.
86. McGregor M. Evaluation of a safety device to prevent needlestick injuries (NI) associated with intravenous (IV) infusions. 18th Annual Meeting of the International Society of Technology Assessment in Health Care. Berlin June 9-12, 2002.
87. McGregor M, Scott H M. Bottom Up or Top Down? How to get Technology Assessments to Influence Policy. Fifth International Conference on the Scientific Basis of Health Services. September 20, 2003. Washington DC USA.
88. McGregor, M, Brophy, J. Health Technology Assessment (HTA). Central or Peripheral. Annual Meeting Health Technology Assessment International, Krakow, Poland. June 2, 2004.
89. McGregor M. HTA use in a Canadian Hospital System. Panel on "bringing HTA into Practice. Annual Meeting Health Technology Assessment International, Rome, June 21, 2005.
90. McGregor M, Brophy J. Needlestick injury in the hospital. Should we always choose zero risk? Union of Risk Management for Preventive Medicine. Second American Congress. Montréal, June 14-15, 2007.
91. Caro J, Kolominsky-Rabas P, McGregor M, Henry D. Informing Decision Makers in Germany: The IQWiG Approach. ISPOR. Toronto. May 6, 2008.

92. McGregor M. Health Technology Assessment from a Local Hospital Prospective. Health Technology Assessment: from Theory to Evidence to Policy. HTAi workshop. Toronto. May 2, 2008.
93. Lapointe A, Brophy J, McGregor M. Sacral nerve stimulation in the management of urinary and fecal incontinence: Experience of two teaching hospitals. Vth Annual Meeting of HTAi, Montréal, July 8, 2008.
94. McGregor M. Budget Creep, an overlooked factor in the sustainability debate. CADTH Symposium. Ottawa. April 5-7, 2009.
95. McGregor M. How do we get the most from HTA? CADTH Symposium. Ottawa April 5-7. 2009.
96. Xie X, McGregor M, Dendukuri N. Comparison of coblation tonsillectomy and electrocautery tonsillectomy in paediatric patients. CADTH Symposium. Ottawa April 5-7. 2009.
97. Lapointe A, McGregor M. La microchirurgie endoscopique transanale (TEM). CADTH Symposium, Halifax. April 19, 2010.
98. Pan I. Dendukuri N, McGregor M. Efficacy and cost-effectiveness of Collatamp-G for infection prophylaxis in cardiac surgery. CADTH Symposium. Halifax. April 19. 2010.
99. McGregor M, Xie X, Dendukuri N. The use of quality instruments to weight evidence from RCTs 2011 CADTH Symposium. Vancouver. April 4, 2011.
100. Xie X, McGregor M, Dendukuri N. Negative Pressure Wound Therapy. Is it effective? 2011 CADTH Symposium. Vancouver. April 4, 2011.
101. Xie X, Nicolau I, McGregor M, Dendukuri N. Subglottic Secretion Drainage Endotracheal Tubes for Prevention of Ventilator-Associated Pneumonia: meta-analysis and cost-effectiveness analysis. CADTH Annual Convention. Ottawa. April 16, 2012.

Invited Presentations

1. McGregor M. The mechanism of action of the nitrites. Karolinska Hospital, Stockholm, 1962.
2. Oriol A, Sekelj P, McGregor M. Limitations of indicator dilution methods in the presence of accelerated recirculation via left-right shunts and bronchial circulation. Proceedings, 5th European Congress of Cardiology, Athens, Sept. 1968. Hellenic Society of Cardiology, Athens. 1970;252-53.
3. McGregor M. L'évaluation des technologies de santé d'un océan à l'autre. Symposium sur L'évaluation des technologies de la santé. Ministère de la Santé et des Services Sociaux, Québec. May 1989.
4. McGregor M. Effectiveness and benefits of medical technology. World Federation of Nuclear Medicine. World Congress, Montreal, Quebec, August 1990.
5. McGregor M. Technological development and internationalization. Its impact on health. Symposium of the Pan American Health Organization and World Health Organization. Quebec City, Canada. March 1991.

6. McGregor M. Peut-on prévoir les impacts financiers, organisationnels et sociaux de l'évolution des technologies médicales? Montreal. L'Association des hôpitaux du Québec. May 1991.
7. McGregor M. Rationalizing and improving the use of technology: a recent Quebec experience. Washington. Joint Congress of the International Society for Quality Assurance and the International Society of Technology Assessment in Health Care. Washington, D.C., May 1991.
8. McGregor M. The Quebec experience of technology evaluation. Twenty-seventh International Hospital Congress and the American Hospital Association, Washington, D.C. June 1991.
9. McGregor, M. Can we limit technology without impairing quality? A Canadian experience of Technology evaluation. Seminar on rationality and use of health technology. Mexico City. November 1991.
10. McGregor M. L'évaluation des technologies au Québec: le conflit des coûts par rapport à l'efficacité et de la sécurité. Colloque Jean-Yves-Rivard. Montréal. March 1992.
11. McGregor M. Cost savings through technology evaluation. The Canadian Institute: Hospital Restructuring, Downsizing, or Rightsizing. Toronto. May 1992.
12. McGregor M. Evaluation of health technologies: the Quebec experience, III Congresso Brasileiro De Saude Coletiva. Porto Alegre et Rio de Janeiro, Brasil. May 1992.
13. McGregor M. Heart disease prevention. What more should we be doing in the light of present knowledge? International Heart-Health Conference. Bridging the Gap: Science & Policy in Action. Victoria, British Columbia. May 1992.
14. McGregor M. Technology evaluation in Quebec: the conflict of cost -vs- efficacy and safety. The Canadian Medical Association. Forum in Ottawa. June 1992
15. McGregor M. Evaluation of medical technologies: is there a role for health professionals? Colloque sur l'évaluation de l'exercice professionnel des médecins <<Parlons Qualité>> Corporation professionnelle des médecins du Québec. June 1992.
16. McGregor M. Is industry doing its share for the assessment of technical evaluation? Seminar on the Future of health research in Canada: health research planning for the year 2000. Joint meeting of the Royal College of Physicians and Surgeons of Canada and the Canadian Society of Clinical Investigation. Ottawa. September 1992.
17. McGregor, M. "Le Conseil d'évaluation des technologies de la santé: A critical view of a New Quebec experience". GRIS - Département de médecine sociale et préventive, Département de médecine familiale, Université de Montréal, March 1993.
18. McGregor, M. Cost-Effectiveness: Cost-Safety. Rationalization of Cardiac Services. Symposium on Planification and Rationalization of Cardiology Care. 150th Anniversary of Université de Montréal. Hôpital Notre-Dame. March 1993.
19. McGregor, M. Technology Assessment (TA). Why this new interest? What it is about? And how it is used? The Alberta Heritage Foundation for Medical Research, Edmonton. May 1993.
20. McGregor M. Technology Assessment. What can it do for me? Montreal Med-Chi Society, May 1993.

21. McGregor M. Cost-Effectiveness. What's it all about. Canadian Society of Industrial Pharmacists. Auditorium Merck Frosst, Kirkland, Quebec. June 1993.
22. McGregor M. Interpreting technology assessment reports. The Canadian Institute, Toronto. June 1993.
23. McGregor M. Can our health services be saved? The role of technology evaluation in light of the Quebec experience. Manitoba Centre for Health Policy and Evaluation, School of Medicine, Winnipeg, Manitoba. October 1993.
24. McGregor M. Nos services de santé; peuvent-ils être sauvés? Colloque: L'avenir du système de santé Québécois. Montreal. 13 mai 1994.
25. McGregor M. Technology use: Who decides? Effects on practice? Royal Society of Medicine, Inc. Washington DC, May 18-20, 1994.
26. McGregor M. Do HTA (Health Technology Assessment) reports influence health policy? Third utilization research and implementation seminar, Victoria, BC, March 24, 1995.
27. McGregor M. Les études du Conseil d'évaluation des technologies de la santé du Québec: à l'origine ou à la remorque des politiques? Colloque du GRIS, Université de Montréal, 12 mai 1995.
28. McGregor M. Health technology assessment. Defining the agenda. Scientific basis of health services. London, England. Oct. 2, 1995.
29. McGregor M. Les travaux du conseil d'évaluation des technologies: la prise de décision dans l'incertitude. L'Association des médecins specialists en santé communautaire du Québec. 10 Novembre 1995.
30. McGregor M. Making policy decisions without evidence. Caro Research Retreat. Sudbury, Mass. Nov. 19, 1996.
31. McGregor, M. How to promote TAs into policy. The example of prostate screening in: "Health Systems Innovation and Technology Assessment. ISTAHC. Special Seminar. L'Ésterel, Jan 31, 1997.
32. McGregor M. Should we screen for prostate cancer in the elderly. Geriatric Grand Rounds. McGill University. March 18, 1997.
33. McGregor M. Discipline Perspectives on Evidence. Symposium on "Resource Allocation Decision-Making for New and Emerging Health Technologies" convened by University of Toronto, Joint Center for Bioethics, the Office of Bioethics Education and Research at Dalhousie University, and CCOHTA. Halifax October 15, 1997.
34. McGregor M. How do we create an ethical basis for health care? Conference on Directions for Canadian Health Care. Toronto, Ont. October 1,2, 1998.
35. McGregor M, Cusson J. Composing the drug list. New costly drugs cause difficult decisions. The Pfizer Lecture. Clinical Research Institute of Montreal. March 9, 1999.

36. McGregor M. Coverage of Costly Drugs. Clinical Epidemiology Rounds. Royal Victoria Hospital March 15, 1999.
37. McGregor M, Hanley J. Screening for prostate cancer. Medical Grand Rounds. Montreal General Hospital, March 23, 1999.
38. McGregor M. Suggestions for better decision-making in resource commitment decisions. Joint Université de Montréal / McGill University. 1999 Summer Program in Epidemiology.
39. McGregor M. Assessing the impact of HTA. Alberta Heritage Foundation for Medical Research workshop, Banff, B.C. May 6, 1999.
40. McGregor M. Decisions on costly drugs: Principles and Process. Réseau FRSQ sur l'utilisation des médicaments. Sherbrooke, Que. May 25, 1999.
41. McGregor M. Suggestions for change in the drug programme. Invited presentation, MSSS, St. Foy, June 28, 1999.
42. McGregor M. Jacob R. Difficult Resource Allocation Decisions. Towards a better Decision Process for Pharmaceuticals. Third International Conference on the Scientific Basis of Health Services. Toronto, October 1-3, 1999.
43. McGregor M. Les dispositifs d'assistance ventriculaire implantable. La commission d'étude sur les services de santé et les services sociaux. Commission Clair. Invited Presentation. MSSS. Montreal. Sept 9, 2000.
44. McGregor M. Allocation of scarce resources. Conference on: The Health Care System in Canada. Is it Broke(n)? Montreal. Oct 25, 2000.
45. McGregor M. Advancing Technologies and Economic Realities. Plenary address, Annual Refresher Course for Family Physicians. Montreal. Sept. 2001.
46. McGregor M. Let not the measurable drive out the relevant – difficult decisions in health care. 12th Annual Christie Memorial Lecture. Meakins-Christie Laboratories, McGill University. Dec 2001.
47. McGregor M. What goes into the Medicare Basket? The McGill Institute for the Study of Canada. Conference on "Diagnostics and Solutions". Montreal. Feb. 14-16, 2002.
48. A personal brief to the Romanow Commission. Invited presentation to the Commission on the Future of Health Care in Canada. Montreal. March 27, 2002.
49. McGregor M. Questions about the Quality of QALYS. 7th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Washington DC. May 19-22, 2002.
50. McGregor M. High Risk Cardiac Care. Who Foots the Bill? The 4th Annual "Cardiac Team" meeting on Management of the Failing Heart. Orford, Québec, Sept 12-14, 2003.
51. McGregor M. HTA in the Hospital. Invited presentation. Capital Health, Edmonton. May 7, 2004

52. McGregor M. Context for Decisions. How one Canadian Health care organization promotes the use of research-based evidence. Executive Training for Research Application. EXTRA. Banff. August 26, 2004.
53. McGregor M. How can we get Technology Assessments to influence health policy and clinical policy? The Annual Meeting of the Danish Center of Evaluation and HTA, October 6, 2004. Aarhus. Denmark.
54. McGregor M. HTA. What is it? Does it work? Could it work better? MBA Program in "Health Care Management" McGill University, February 9, 2005.
55. McGregor M. Priority Setting. Whose Priorities? In: An Invitational Symposium for HTA Researchers and Policy Makers, on "Current Issues for Health Technology Assessment in Canada. The Canadian Coordinating Office for Health Technology Assessment. Ottawa. April 26, 2005.
56. McGregor M. On increasing the impact of HTAs. Invited Plenary address, 10th annual meeting of the International Society for Pharmacoeconomic and Outcomes Research. Washington DC. May 18, 2005.
57. McGregor M. What decision makers want and what they have been getting. Invited Noon lecture. The Ulysses International Masters Program in Health Technology Assessment and Management. Ottawa. May 25, 2005.
58. McGregor M. Health Technology Assessment. A great idea not fully realized. University of British Columbia and Vancouver Coastal Health Research Institute June 6, 2005.
59. McGregor, M. Promoting the use of research-based evidence in health-care organizations. Executive Training for Research Application. EXTRA. Program. Banff. August 18, 2005.
60. McGregor, M. SUSTAINABILITY?. The question behind the debate. Meeting on Cancer Systemic Therapy Affordability Strategies. Cancer Care Ontario and the Ontario Drug Benefits Program. Toronto, September 30, 2005.
61. McGregor, M. Évaluation des technologies. L'avenir ? FORUM. L' ÉTS au Québec....bâtir le future ensemble. Vers une vision commune de la production en evaluation des technologies. Agence d'évaluation des technologies et des modes d'intervention en santé. Montréal. October 28, 2005.
62. McGregor M. Les aiguilles sécuritaire: Les employer ou non ? Colloque. L'évaluation des technologies et des modes d'intervention dans les établissements universitaire: répondre aux defies de la decision en santé. Montréal. 17 mars 2006.
63. McGregor M. Context for decisions: how one organization promotes the use of research-based evidence. Executive Training for Research Application. (EXTRA). Banff, Alta. August 24, 2006.
64. McGregor M. L'unité d'évaluation des technologies, CHUM/CUSM. Conférence des CHU du Québec. Mission des CHU de France. Montréal. 11 décembre 2006.
65. McGregor M. Health Technology Evaluation Before Technology Acquisition: A new Approach to Hospital Decision Making. Plenary Session, Annual Meeting of the Ontario Thoracic Society and the Ontario Lung Association. Toronto. 2007.

66. McGregor M. Health technology evaluation before acquisition. Decision making at the local level. Evidence, Economics, and Ethics for Tough Decision Making. And Invitational Conference convened by Canadian Agency for Drugs and Technologies in Health and Dalhousie University. Moncton, New Brunswick, May 4, 2007.
67. McGregor M. Putting EBM into Practice. The use of Evidence in Hospital Policy Decisions. Johnson & Johnson New Brunswick NJ. Annual Convention. November 27, 2007.
68. McGregor M. Context for Decisions. How one organization promotes the use of research-based evidence. Executive Training for Research Application (EXTRA). Kananaskis, Alberta, August 15, 2007.
69. McGregor M. Needlestick Injury in the Hospital. Should we always choose zero risk? The union of Risk Management for Preventive Medicine (URPMPM) and CIRANO. Montréal. June 15, 2007.
70. McGregor M. Evaluation Before Acquisition: a hospital approach to technology decision making. Conference on "Evidence, Economics, and Ethics for Tough Decision Making". Canadian Agency for Drugs and Technologies in Health and Dalhousie University. Moncton, New Brunswick, May 4, 2007.
71. McGregor M. Prevention of Needlestick Injury in the hospital. Is Zero the only Acceptable Risk? Keynote, Plenary session, XV Cochrane Colloquium. Sao Paulo, Brazil. October 27, 2007.
72. McGregor M. Health Technology Evaluation Before Acquisition: a hospital approach to technology decision making. Better Breathing Conference of the Ontario Lung Association. Toronto. February 1, 2007.
73. McGregor M. Medicare, Wait times, and HTA. Division of Respiriology Annual Retreat. Calgary, March 15, 2008.
74. McGregor M. Health Technology Assessment from a Local Hospital Perspective. In: Health Technology Assessment: From Theory to Evidence to Policy. Workshop and Forum organized by McMaster University. Toronto, May 2, 2008.
75. McGregor M. HTA in the hospital. A 6-year experience. HTAi Vth Annual meeting. Plenary session. Montréal. July 9, 2008.
76. McGregor M. HTA in health systems and health decision-making. In: CIHR Training Programme in Health Technology Assessment and Transfer in General and Oral Health. Montréal. July 15, 2008.
77. McGregor M. Promoting the Use of Research-Based Evidence in Health-Organizations. In: Executive Training for Research Application (EXTRA). Kananaskis, Alta, August 14, 2008.
78. McGregor M. Entrepreneurial Leadership. Dobson Centre for Entrepreneurial Studies. McGill Univ. Feb 12, 2009.
79. McGregor M. Context for Decisions: How One Organisation Promotes the Use of Research-Based Evidence. In: Executive Training for Research Application (EXTRA). Mont Tremblant Québec, August 14, 2009.

80. McGregor M. Intrepreneurial Leadership. Desautels Faculty of Management. McGill University. Jan 26. 2010.
81. McGregor M, Goldbloom V, Castonguay C. How do you build a health care system? The quiet revolution in Quebec. International Masters for Health Leadership. McGill. June 6, 2010.
82. McGregor M. Les coûts de l'acquisition des technologies de la santé. Hôpital Sacre-Cœur. June 1, 2010.
83. McGregor M. A Hospital Perspective. Public Policy Forum. In: Innovating Health: Public engagement in health technology assessments and coverage decisions. June15, 2010. Montréal.
84. McGregor M. Promoting Use of Evidence in Health-care Decisions. EXTRA Program. Module one. Mont Tremblant. Québec. Aug 11. 2010.
85. McGregor M. HTA from a Local perspective- Hospital. Health Technology Assessment: from Theory to Evidence to Policy. PATH Research Institute. Toronto. October 22, 2010
86. McGregor M. Paying for Technology. The cost of ignoring opportunity costs. There is no free lunch. THETA Collaboration. SPECIAL WEDNESDAY ROUNDS. Toronto, October 20, 2010
87. McGregor M. The connect between wait times, sustainability and HTA. Health Care, Technology and Place (HCTP). Symposium on: The Career of Health Technology: Perspectives on Innovation, Assessment, and Use. Toronto. March 24, 2011.
88. McGregor M. Promoting Use of Evidence in Health-care Decisions. EXTRA Program. Module one. Mont Tremblant. Québec. Aug 11. 2011.
89. McGregor M. On Leadership. Desautels Faculty of Management. McGill University. Jan 26, 2011.
90. McGregor M. HTA in the Canadian Healthcare System. CADTH Science Week. Ottawa. Oct. 11, 2011.
91. McGregor M. HTA From a Local Perspective. Hospital. PATH Institute Policy Forum. Toronto. October 21, 2011.
92. McGregor M. HTA. What is it? Why do we need it?. MentecNorth. Annual Conference. Montréal. April 18, 2012.
93. McGregor. M. Hospital Based HTA. Clinical Epidemiology Program. Ottawa Hospital Research Institute. November 19, 2012.
94. McGregor M. Some Random Reflections of an elderly Cardiologist on Our Healthcare System. McGill Division of Clinical Epidemiology Seminar. Montreal. October 17, 2013.